In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Data, Data Everywhere

Executive Summary

As heaps of genetic and chemical data pile up in research databases, Molecular Applications Group is trying to build a business in bioinformatics. But the industry is so new, neither the goals nor the rules are clear. Pricing, service, and standardization are key issues as MAG and its competitors look for business models that not only work today, but can evolve as well.

You may also be interested in...



Industry Pushes For Revised PFAS Definition In California Bill Seeking Cosmetic Ban

The Personal Care Products Council and other industry groups suggest they will support AB 2771 if amendments are made to promote international harmonization, among other changes. Already they advocated successfully for the bill’s scope to be limited to intentionally added PFAS, not “the mere presence of trace levels of fluorine in the product.”

Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions

The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.

Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use

Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV000726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel